[Skip to Navigation]
Sign In

June 2024, Vol 160, No. 6, Pages 593-691

Viewpoint

Nails as Dynamic, Not Static, Entities—Rethinking the Approach to Nail Disorders

Abstract Full Text
JAMA Dermatol. 2024;160(6):595-596. doi:10.1001/jamadermatol.2024.0400

This Viewpoint discusses the need for a broader approach to nail pathology, in which infectious, inflammatory, systemic, and structural factors are considered.

Editorial

Improved Dermatologist, Patient, and Oncologist Collaboration Needed During Cancer Drug Development

Abstract Full Text
JAMA Dermatol. 2024;160(6):597-599. doi:10.1001/jamadermatol.2024.0048
Original Investigation

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial

Abstract Full Text
JAMA Dermatol. 2024;160(6):600-605. doi:10.1001/jamadermatol.2024.0284

This randomized clinical trial compares the efficacy, safety, and tolerability of daily oral minoxidil, 5 mg, with twice-daily topical minoxidil, 5%, for 24 weeks in the treatment of male androgenetic alopecia.

Weekly Pulsed Dye Laser Treatments for Port-Wine Birthmarks in Infants

Abstract Full Text
JAMA Dermatol. 2024;160(6):606-611. doi:10.1001/jamadermatol.2024.0293

This case series examines the improvement in port-wine birthmark clearance from before to after once-weekly pulsed dye laser therapy in patients younger than 6 months.

Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial

Abstract Full Text
JAMA Dermatol. 2024;160(6):612-619. doi:10.1001/jamadermatol.2024.0408

This nonrandomized controlled trial analyzes the efficacy and safety of erenumab, an anti–calcitonin gene-related peptide receptor monoclonal antibody, for rosacea-associated erythema and flushing.

Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders

Abstract Full Text
has audio
JAMA Dermatol. 2024;160(6):621-630. doi:10.1001/jamadermatol.2024.0594

This cross-sectional study examines the stigmatization of children and adolescents associated with the visibility and severity of chronic skin disorders.

Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy

Abstract Full Text
JAMA Dermatol. 2024;160(6):631-640. doi:10.1001/jamadermatol.2024.1037

This economic evaluation examines the cost-effectiveness of HLA-B*15:02 genotyping in Asian Australian patients with epilepsy.

Brief Report

Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial

Abstract Full Text
JAMA Dermatol. 2024;160(6):641-645. doi:10.1001/jamadermatol.2024.0257

This nonrandomized trial examines outcomes with treatment with guselkumab for patients with pityriasis rubra pilaris.

Current State of Dermatology Mobile Applications With Artificial Intelligence Features

Abstract Full Text
JAMA Dermatol. 2024;160(6):646-650. doi:10.1001/jamadermatol.2024.0468

This cross-sectional study identifies and characterizes the current English-language artificial intelligence dermatology mobile applications available for download in US application stores.

Editor's Note

Potential Role of Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Rosacea Flushing and Erythema

Abstract Full Text
JAMA Dermatol. 2024;160(6):620. doi:10.1001/jamadermatol.2024.0397
Review

Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials: A Systematic Review

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(6):651-657. doi:10.1001/jamadermatol.2024.0053

This systematic review evaluates heterogeneity and quality of clinician-reported and patient-reported outcome measures for assessing dermatologic adverse events related to systemic cancer treatment.

Consensus Statement

Rosacea Core Domain Set for Clinical Trials and Practice: A Consensus Statement

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(6):658-666. doi:10.1001/jamadermatol.2024.0636

This consensus statement uses the Delphi process to develop a core domain set for rosacea clinical trials and practice.

Images in Dermatology

Trichomegaly Due to Panitumumab

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(6):667. doi:10.1001/jamadermatol.2024.0642

This case report describes an adult male patient with a severe acneiform eruption on his chest and back.

Chloracne

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(6):668-669. doi:10.1001/jamadermatol.2024.0928

This case report describes hyperpigmented, pruritic lesions on the patient’s face and chest that worsened over the previous 3 weeks.

JAMA Dermatology Clinicopathological Challenge

Red Nodule on the Scalp in a Healthy Young Man

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(6):670-671. doi:10.1001/jamadermatol.2024.0146

A man in his 40s was referred for an 8-mm red, firm, mobile nodule with irregular red lacunae and vessels and an absence of septa. What is your diagnosis?

Chronic Progressive Pink-Yellow Papules and Nodules in a Middle-Aged Man

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(6):672-673. doi:10.1001/jamadermatol.2024.0227

A 38-year-old man presented with numerous pink-yellow firm papules and nodules on the bilateral elbows for 10 years spreading to the hands and knees in the past year. What is your diagnosis?

JAMA Dermatology Patient Page

Onychomycosis

Abstract Full Text
free access
JAMA Dermatol. 2024;160(6):691. doi:10.1001/jamadermatol.2023.5194

This Patient Page describes the risk factors, clinical features, diagnosis, and treatment of onychomycosis.

Research Letter

Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

Abstract Full Text
JAMA Dermatol. 2024;160(6):674-676. doi:10.1001/jamadermatol.2024.0403

This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis.

Methotrexate Use and Risk of Interstitial Lung Disease in Dermatomyositis

Abstract Full Text
JAMA Dermatol. 2024;160(6):676-678. doi:10.1001/jamadermatol.2024.0785

This cohort study examines the association between methotrexate use and interstitial lung disease in patients with dermatomyositis.

Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab

Abstract Full Text
JAMA Dermatol. 2024;160(6):678-681. doi:10.1001/jamadermatol.2024.1075

This post hoc analysis of PIONEER I and II randomized clinical trials assesses whether receiving adalimumab is associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.

Observation

Treatment of Keratosis Lichenoides Chronica With Upadacitinib

Abstract Full Text
JAMA Dermatol. 2024;160(6):681-682. doi:10.1001/jamadermatol.2024.0755

This case report describes a 30-year-old man presenting with 1-year history of nonitchy red papules and patches who was subsequently treated with upadacitinib.

Keratosis Pilaris–Like Reaction Associated With Chromatin Remodeling Complex Inhibition in Uveal Melanoma

Abstract Full Text
JAMA Dermatol. 2024;160(6):682-685. doi:10.1001/jamadermatol.2024.1137

This case series describes a constellation of novel adverse reactions in 3 of 9 patients with uveal melanoma receiving treatment targeting activity of the Brahma-associated factor chromatin remodeling complex.

Comment & Response

ALK-Positive Histiocytosis—A Distinct Histiocytic Entity Deserving Recognition

Abstract Full Text
JAMA Dermatol. 2024;160(6):685-686. doi:10.1001/jamadermatol.2024.0750

ALK-Positive Histiocytosis—A Distinct Histiocytic Entity Deserving Recognition—Reply

Abstract Full Text
JAMA Dermatol. 2024;160(6):686. doi:10.1001/jamadermatol.2024.0743

Relevance of Human Herpesvirus 6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms

Abstract Full Text
JAMA Dermatol. 2024;160(6):687. doi:10.1001/jamadermatol.2024.0885

Relevance of Human Herpesvirus 6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms—Reply

Abstract Full Text
JAMA Dermatol. 2024;160(6):687-688. doi:10.1001/jamadermatol.2024.0876
Correction

Error in Table

Abstract Full Text
free access
JAMA Dermatol. 2024;160(6):688. doi:10.1001/jamadermatol.2024.1011

Error in Study Type

Abstract Full Text
free access
JAMA Dermatol. 2024;160(6):688. doi:10.1001/jamadermatol.2024.1342
JAMA Dermatology Masthead

JAMA Dermatology

Abstract Full Text
free access
JAMA Dermatol. 2024;160(6):593. doi:10.1001/jamadermatol.2023.3988
×